Commentary: Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)553-554
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Volume38
Issue number5
DOIs
Publication statusPublished - Sep 2013

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this